Gut Health Startup The Good Bug Raises INR 100 Cr

Microbiome-focused startup The Good Bug has raised ₹100 crore in Series A funding led by Fireside Ventures. The gut health company will utilize the capital to expand its probiotic product portfolio, enhance clinical research capabilities, and build in-house manufacturing infrastructure. The Good Bug's science-backed formulations target digestive health, immunity and metabolic conditions through specific probiotic strains. The funding will support market expansion beyond metro cities into tier 1-2 markets through modern trade and e-commerce channels. With the Indian probiotics market projected to reach $300 million by 2027, the startup plans to introduce 8-10 new SKUs addressing specific health conditions. A portion of the investment will go towards consumer education initiatives about gut microbiome science and its impact on overall wellness. The company differentiates itself through clinically validated formulations and transparent labeling of strain-specific benefits. This funding round comes amid growing consumer awareness about preventive healthcare and increasing demand for science-backed wellness products in India.